Dyadic International, Inc. Share Price Other OTC
Equities
US26745T1016
Biotechnology & Medical Research
Sales 2024 * | 4.2M 350M | Sales 2025 * | 6.1M 509M | Capitalization | 43.56M 3.63B |
---|---|---|---|---|---|
Net income 2024 * | -22M -1.84B | Net income 2025 * | -31M -2.59B | EV / Sales 2024 * | 10.4 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 7.14 x |
P/E ratio 2024 * |
-2.26
x | P/E ratio 2025 * |
-1.66
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 48.91% |
Latest transcript on Dyadic International, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Mark Emalfarb
FOU | Founder | 69 | 01/79/01 |
Ping Rawson
DFI | Director of Finance/CFO | 48 | 01/16/01 |
Joseph Hazelton
COO | Chief Operating Officer | 48 | 09/21/09 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mark Emalfarb
FOU | Founder | 69 | 01/79/01 |
Jack Kaye
BRD | Director/Board Member | 80 | 01/15/01 |
Michael Tarnok
BRD | Director/Board Member | 69 | 12/14/12 |
1st Jan change | Capi. | |
---|---|---|
+1.77% | 42.75B | |
+47.70% | 41.61B | |
+12.24% | 41.34B | |
-8.83% | 26.59B | |
+7.44% | 25.49B | |
-23.01% | 18.12B | |
+30.56% | 12.24B | |
-1.82% | 11.76B | |
+8.35% | 11B |